Affordable Access

deepdyve-link
Publisher Website

Pharmacokinetics and safety in cynomolgus monkeys of a monoclonal antibody targeting human scavenger receptor class B type-1 for hepatitis C treatment.

Authors
  • Flores, M Victoria
  • Corbau, Romuald G
  • Guionaud, Silvia
Type
Published Article
Journal
Antiviral Therapy
Publisher
International Medical Press
Publication Date
Jan 01, 2013
Volume
18
Issue
6
Pages
775–784
Identifiers
DOI: 10.3851/IMP2570
PMID: 23702590
Source
Medline
License
Unknown

Abstract

The pharmacokinetics and toxicology results were in accordance with the pharmacology of the antibody mechanism. The elevation of total cholesterol was dose-dependent and did not exceed a twofold increase. The safety study indicated no adverse effects during the treatment or in the pathology analysis at any of the doses tested.

Report this publication

Statistics

Seen <100 times